(Q35056073)

6 August 2017

1 reference

title

Development potential of rifalazil (English)

1 reference

6 August 2017

David M Rothstein

1

1 reference

6 August 2017

Arthur D Hartman

series ordinal

2

1 reference

6 August 2017

Michael H Cynamon

series ordinal

3

1 reference

6 August 2017

Barry I Eisenstein

series ordinal

4

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

1 reference

6 August 2017

12

1 reference

6 August 2017

2

1 reference

6 August 2017

255-271

1 reference

Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Structural mechanism for rifampicin inhibition of bacterial rna polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Accumulation of KRM-1648 by Mycobacterium aurum and Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. SENTRY Participants Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

rpoB mutation conferring rifampin resistance in Streptococcus pyogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Advances in DNA gyrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Antibiotic resistance problems with Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Resistance of Helicobacter pylori to antibiotics and its impact on treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Helicobacter pyloriInfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Treatment of antibiotic-resistant Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Genome sequencing and our understanding of chlamydiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Chlamydia and Chlamydiales: more than meets the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Closing in on Chlamydia and its intracellular bag of tricks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Ultrastructural analysis of developmental events in Chlamydia pneumoniae-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Chlamydia trachomatis genes whose products are related to energy metabolism are expressed differentially in active vs. persistent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Chlamydia pneumoniae as a respiratory pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Childhood trachoma in a nonendemic area. Danish trachoma patients and their close contacts, 1963 to 1973

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Chlamydia trachomatis: impact on human reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Untreated gonococcal and chlamydial infection in a probability sample of adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

New tools for coronary risk assessment: what are their advantages and limitations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Cardiovascular disease. Does inflammation cut to the heart of the matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Arterial inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Evidence for infectious agents in cardiovascular disease and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Chlamydia pneumoniae pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Chlamydia pneumoniae and atherosclerosis -- what we know and what we don't

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Clinical practice. Antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.255

10.1517/13543784.12.2.255

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference